Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

Cancer research · Multiple myeloma

Ciltacabtagene autoleucel (cilta‑cel) is a B‑cell maturation antigen‑directed chimeric antigen receptor T‑cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1–3 prior LOT) trials, which reported high response rates and prolonged survival.

Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1–3 prior LOT) trials, which reported high response rates and prolonged survival. In CARTITUDE-1 and CARTITUDE-4, rates of all-grade parkinsonism were 6% and < 1%, respectively, while rates of cranial nerve palsy were 3% and 9%, respectively. This study aimed to characterize new‑onset non‑immune effector cell‑associated neurotoxicity syndrome (non‑ICANS) neurologic events (NEs) among patients with RRMM receiving cilta‑cel after 1–3 or ≥ 4 prior LOT.

This real‑world analysis evaluates the incidence and timing of non‑ICANS neurologic events—such as parkinsonism, cranial nerve palsy, and Guillain‑Barré syndrome—in patients treated with cilta‑cel, providing clinicians with relevant safety data outside the controlled environment of pivotal trials.

Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Original source

Related signals